Jun 17, 2020

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Part 1: A roundtable discussion featuring Drs John Heymach, Leora Horn, Melissa Johnson and Benjamin Levy.

• Biomarker assessment for patients with metastatic non-small cell lung cancer (NSCLC) (00:00)
• Selection of first-line treatment for patients with metastatic NSCLC without actionable tumor mutations; role of immune checkpoint inhibitors (6:48)
• Case (Maria Picton, MD): A man in his mid-80s and previous smoker with metastatic adenocarcinoma of the lung and pleural effusion receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pembrolizumab (17:44)
• Case (G Richard Polkinghorn, MD): A man in his early 50s with metastatic squamous cell carcinoma of the lung receives ramucirumab and docetaxel as second-line therapy (23:16)
• Use of immune checkpoint inhibitors for patients with a history of autoimmune disease (37:40)
• Case (Dr Polkinghorn): A woman in her early 60s and current smoker with multiple sclerosis and COPD receives nivolumab for metastatic NSCLC and attains a complete remission (44:35)
• Treatment of metastatic NSCLC with actionable tumor mutations, including ALK rearrangements (48:51)
• Case (Joseph T Martins, MD): A woman in her mid-70s and previous smoker with metastatic NSCLC and a MET mutation (59:18)
• Case (Margaret A Deutsch, MD): A man in his mid-60s, a never smoker, with metastatic adenocarcinoma of the lung and a KIF5B-RET fusion receives cabozantinib (1:02:22)
• Activity and tolerability of the selective RET inhibitors pralsetinib and selpercatinib; preliminary results from the Phase III ADAURA trial evaluating adjuvant osimertinib (1:06:13)
• Management of metastatic NSCLC in the era of COVID-19; preliminary results from the TERAVOLT registry on the impact of COVID-19 on the care of patients with lung cancer (1:11:55)

CME information and select publications